Stevanato Group S.p.A. (NYSE:STVN) Q3 2023 Earnings Call Transcript

Page 6 of 6

Franco Moro: I can repeat what we delivered in the past about situation in buyers and in consumable for the diagnostic services. But it’s something that represents one part of a highly differentiated portfolio in our revenue. So we are impacted a very limited way. And as you know, we haven’t been able to compensate with the expansion in other therapeutic areas or product lines, overweighting the space for high-value solution for biologics.

John Sourbeer: I got it. So just to clarify on that, so I guess you know in Drug Containment Solutions you know there’s not areas where you’re seeing any customers destocking coming down?

Franco Moro: No, no, it’s the opposite. We have to execute properly our capacity expansion plans to meet their strong demand. It’s the opposite. There is no this kind of situation you are referring to in the high-value solution.

John Sourbeer: Got it. Thank you for taking the questions.

Operator: [Operator Instruction] Ms. Miles, gentlemen, there are no more questions registered at this time.

Lisa Miles: Thank you everyone for joining us today for the Stevanato Group third quarter 2023 earnings call. We look forward to speaking with you in the future. Thank you.

Operator: Ladies and gentlemen, thank you for joining. The conference is now over. You may disconnect the telephones. Thank you.

Follow Stevanato Group S.p.a. (NYSE:STVN)

Page 6 of 6